B+
Bull case
25%
Probability
Target price
$81.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
COO
Cooper CompaniesANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$69.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$54.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-10
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+93.7
Score
AI commentary
Post-print coverage is negative around weak guidance and the CooperVision inventory overhang, despite a Q3 earnings beat, strong free cash flow, and buyback expansion. No reliable post-print analyst target changes, estimate revisions, options data, short-interest data, employee sentiment, or social coverage were supplied; confidence is therefore moderated. The prior bullish monitoring thesis has shifted to cautious event-driven monitoring.
RankAlpha Sentiment Codex - 2026-09-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-09eventQ3 FY2026 print and guidance resetMedium impact
Revenue rose 1% to $1.066 billion, non-GAAP EPS rose 4% to $1.15, and free cash flow rose 66% to $273 million. However, CooperVision was flat and management expects Q4 CooperVision organic growth of -2% to 0% and Q4 non-GAAP EPS of $1.05-$1.09. [#SEC-8K-2026-09-09]
2026-09-23catalystStrategic-review execution and capital allocationMedium impact
The Board retained CooperSurgical, expanded the repurchase authorization from $2 billion to $3 billion, and outlined commercial, efficiency, logistics, and innovation initiatives. CooperVision’s Vision Centre is scheduled to open September 23, 2026. [#SEC-8K-2026-09-09]
2026-10-31catalystCooperVision inventory digestionMedium impact
Management said proactive U.S. channel-inventory reduction weighed on Q3 results and will continue affecting Q4, creating near-term execution and estimate-risk pressure. [#SEC-8K-2026-09-09]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-10 • Updated nightlySource: Internal modelMethodology